Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nutriman,
Although I have some knowledge I am not the most technically savvy on this stuff. Are they adding Genasense in with T cell immune system therapy? I will still look it up a research, just wondering if you know.
Exactly. Frank I am going off of the middle of the month. The last one I can find was on September 15th. So that would make it a nice round even number in months.
I think we will have an approval from the EMEA before FDA. Just my opinion. To me everything is pointing that way. Patents etc. The EMEA if you have not looked put out a release asking for the Agenda trial to confirm the positive results.
With that said, I would expect a possible marketing and distribution partnership with someone in Europe. Hopefully the final DMB meeting will push this and possibly the EMEA over the tipping point.
I hear you there.
I think Genta will find a way. I just would like them to find a better way then the current financial deal. Welcome eklipze. People on here are a big help in double checking your DD.
I hate weekends! No market to watch.
I don't like politicians either, from personal interactions they don't care about any of us.
So anyway, what if Genta has been naked shorted the R/S does not happen and we have some partner news or a Ganite sale this month?
Man we could be setting up pretty good.
I have worked for the Government and paid 90 dollars a month for health insurance. I am currently self employed and love it. I can pic my own plan down to exactly what I need. Our daughter two years ago was in the hospital for 14 days. The insurance picked it up all but 4000. The hospital wrote off 2000 and I paid 2000. So I am very happy with what I pay for on an 18000 dollar bill.
Long story short I am not everyones dad, so don't make me pay their bills.
Now lets get back to Genta please.
So if it is a huge tax cut for everyone, where is the money going to come from? The sky. Who pays for Medicad right now? The tax payers.
In addition our federal governments sole duty when formed was to protect the borders and our interests abroad. What happened?
I have personally worked in Africa, the Middle East, Canada, South America, Europe and Central Asia. And I can with a fact tell you our Health care is leaps and bounds above them all. I am not sorry that money motivates people, motivated people should be rewarded and flip side of that coin for lazy people. And I also drive a very well taken care of FORD F-150 that is 10 years old so I can be responsible and pay my bills.
At that lets stick to Genta please.
Ok back on subject.
I have one for you all. What if this thing is being naked shorted the R/S is voted down and Genta announces a partnership this month? I know that is all very wishful thinking, could happen though.
LOL
Actually our health care is not priced that bad. I am on an individual plan that covers me and 4 dependents with dental. It costs around 400 a month. The problem is people do not buy insurance, instead they buy a fancy car. Same reason why people are be foreclosed on no savings and no clue. I personally do not want the government in my life anymore than I have too.
And yes we do have a healthcare plan for the poor, it is medicad. Unfortunately I can tell you from personal experience that people abuse the crap out of it. How about being called to a house at 2 am cause someone has not taken a crap in a week. And the ambu bill paid by medicad.
Hospitals also code stuff and it get written off to the federal government. Emergency operation procedures gets reduced with government funds all the time. Just some people want control, that is all it amounts too. When someone walks in with a fake SSN card and they treat them by the time they find out these people are down the road. So the government foots the bill. And I have two relatives that can't stand the Canadian healthcare system.
No offense just pisses me off. Not in reply to you Frank, just elaborating on yours.
The pps is down because of poor business management.
Upon partnership market cap 250 mill to 500 mill may spike to more but will not hold.
Upon approval 1 billion
After successful year of sales or maybe even one quarter 2 billion plus
I agree. I think the best thing they can do for all if we see very good news on this DMB is to sign a marketing and distribution deal. Then let the 2009 notes default by not doing a R/S and pay them off in full with cash from the marketing and distribution arrangement.
Good pipeline, poor business management and need a stronger Board that has shareholders interests at heart.
By the way I am not a computer nerd, just surfing while I listen to Fox business. They are talking about W. Buffet.
In my opinion it would be very good. They could cover the rest of the year and maybe more.
Ganite is the big example of just one of the many problems with Genta. This stock is not in penny land because of the pipeline denials alone. They have a great pipeline and great potential. I believe this company can be turned around, and this is why I own Genta. The problem is poor business management.
Look at the sales on Ganite from year to year. You will see what I am talking about.
If they planned on not marketing the drug hard, or felt they could not, it should have been sold to help increase revenue. If they did this we would not be in a poor financial arrangement right now. They had all last year to plan ahead and failed.
Now I know people are going to say "I looked at the bio's and these are solid people with impressive resumes" It is what they are doing now that counts not 2-3 or more years ago. They need to manage the company better and the board needs to step up to the plate.
Sorry rambling.
Should see news on the DMB at the Middle of the Month.
I voted no on the R/S because I think they can get a better financing deal than what they signed. If the meeting is positive or very positive I think they should find a better deal and pay this one off. I know people say the doors will close, they have been in this position before. If the boards feedback is very positive with all the news of drugs trials stopped for melanoma in the last month people should be lining up. Because it is a confirmatory trial of good news like the EMEA stated.
JMHO If they see very positive results at this review they will have more leverage and should go shopping for a better financial deal.
They are not in default till 105 days after the initial closing if no R/S
Yes they are wrong, obviously this was put out, so thats news about the trial. LOL
I do not know I am looking and speculate that this is why the shareholders meeting may have been moved back.
No, they have to get approval from the 2009 note holders if they want to do a reverse split outside of a 1 to 25 up to a 1 to 50 R/S. No big deal people are just reading to fast.
If they could do it anyway we would not be voting on it. They had to spend money to put on the meeting do the vote etc.
"The DMC is a group (typically 3 to 7 members) who are independent of the company sponsoring the trial. At least one DMC member will be a statistician. Clinicians knowledgeable about the disease indication should be represented, as well as clinicians knowledgeable in the fields of any major suspected safety effects (e.g. nephrology, cardiology). A few long, visible trials may include an ethicist or even a representative from a patient advocacy group. The DMC will convene at predetermined intervals (three to six months typically) and review unblinded results, i.e. results split by experimental and control arms. The DMC has the power to recommend termination of the study based on the evaluation of these results. There are typically three reasons a DMC might recommend termination of the study: safety concerns, outstanding benefit, and futility."
It is also known as a DMB. Note if it shows outstanding benefit. This is the meeting everyone should be looking forward to take place.
The statement from the previous post was put out in the last PR, that some except Bio on this board said did not say anything new.
This will be the last meeting of the DMB for Agenda trial.
The Data Monitoring Board will convene in May 2009 for its final review of safety and futility analysis, and we look forward to that meeting. We remain grateful for the support from our investigators and patients for the timely completion of this critically important trial.”
Anyone able to find a date on this meeting yet?
No, I don't think so. They need to get it together and work out a better financial arrangement, partnership etc. If they R/S it will be on your back and you may never get your money out. If the product is good, which it is they need to work a different financial arrangement. This is your chance to voice your distaste for the financial arrangement.
The reason why they worked this out IMHO is to buy them time or they do not want to give up some of the rights to the drug. Sometimes it is best to not do things like a bull in a china shop, work a deal and move on with the rest of the pipeline.
I could be wrong. This is JMHO.
I voted no also. I think if they have a good meeting about safety and futility I think the management can get a better deal. And they should. That is the responsible thing to do at this point for all parties minus the 2009 note holders involved.
This is true just might be a bumpy ride. Now remember to split anything other than between 1/25 to 1/50 they need 2009 note holder approval. This is just a protection measure for those note holders.
Now for sg lets do some math:
1,000,000 shares / 100 = 10,000 shares
If you did not pay attention and got caught up in the moment and bought at .025 cents. That is 25 G
So to realize your investment that is 2.5 dollars a share.
Market Cap full dilution at 2.5 a share is 15 Billion.
Market Cap full dilution at 1 dollar a share 6 billion.
At .50 cents 3 billion
Now comparison is around a 2 to 3 billion cap on first year sales of other companies JMHO. So if you think that they will get approval it may be worth the risk. But if they do not get something going soon and do a worse case R/S it will take a long time to get your money back out.
Long story short do your math before investing.
Either way this is a risky investment. I am in anyway, I believe we will see a better financing deal coming through. And if not, then you will have to hang on for a long rough ride.
Not in this case. They made a desperation financing deal to keep the doors open and the finance deal puts them over the authorized shares.
This is why most retail investors in my opinion will vote no.
This makes sense for some investors. For me this is a free play. If what I believe what will happen by the end of the month happens, the train will have already left the station before anyone realizes what is going on.
However I have a much higher tolerance for risk than others. Everyone knows if they can't afford to lose it they should get out. I don't think telling them everyday is going to change anything.
Well with all these stories of companies closing up shop on cancer drugs. I think we are in the drivers seat. Just need a positive on this upcoming review meeting.
Kind of grumpy today.
You must have held some of Chrysler's bonds. Sorry.
I agree with you all's decision to go get some more of your money back.
Another story.
Noting the Cell Genesys GVAX story at the bottom. hmm
Genta is not looking so bad?
Drug stocks mixed, Sequenom tanks on test delay
10:34a ET April 30, 2009 (MarketWatch)
BOSTON (MarketWatch) -- Drug stocks were mixed in early action Thursday as shares of biotech group Sequenom Inc. tanked on news that the launch of its new test for Down Syndrome will be delayed.
The Amex Pharmaceutical Index climbed 0.9% to 239.54 while the Amex Biotechnology Index fell 1.9% to 640.79.
The Dow Jones Industrial Average advanced over 100 points to 8,291 after several companies reported better-than-expected quarterly earnings.
Big Pharma had a largely positive start, with shares of Pfizer Inc. , Schering-Plough Corp. , Novartis AG, Sanofi-Aventis and Johnson & Johnson all climbing about 2%.
Sequenom shares, meanwhile, plunged more than 75% to $3.72.
Late Wednesday, Sequenom announced that the launch of its SEQureDx test for Down Syndrome will be delayed due to the discovery that important test data supporting the product's validity were mishandled by employees.
Despite the setback, Sequenom said it is moving forward with the development of a similar test for the genetic disorder. The company said it hopes to have a validated test ready during the fourth quarter.
Sequenom also reported a widened first-quarter loss of 29 cents a share, compared with 19 cents a share for the 2008 quarter.
Also feeling pain were shares of cancer vaccine developer Cell Genesys, down 21% at 53 cents a share.
The biotech group said it has ended its GVAX cancer vaccine program and transferred its regulatory filing materials to Johns Hopkins University. Cell Genesys will retain some commercial rights to any future GVAX products.
Cell Genesys also reported a first quarter net loss of 10 cents a share, compared with 29 cents a share. The company has eliminated about 95% of its workforce.
Cell Genesys added that it is still pursuing strategic alternatives for the company, which could include liquidation.
Holder do not even get me started. LOL
True enough. Lets not Yahoo up our board.
EPS on them down year to year
mishandling of testing
I would stay away till the smoke settles. Next thing you know someone comes in with a lawsuit cause they invested off of the testing results and impending launch of the product.
This thing IMHO could go way south in a hurry.
Of course I do not know tons about the company though so do your own DD.
not as high speed as you lol. I do not use Bollinger Bands. Just EMA and RSI or OBV. Sounds good though.
For all that are interested. Go to MD Anderson Cancer Center web page and click on the radio casts. Its called Patient Power. They discuss breaking treatments in all kinds of cancer and prevention. Real informative.
Sorry, just a heads up for anyone who did not know.
Link attached. If Genta produces same results as last time it looks to be an equal 36% rate. Would be great for patients if both were approved.
http://skincancer.about.com/od/glossary/g/ipilimumab.htm
Did some checking again and it can cause some very nasty reactions such as renal failure among others. Do not know if that has been tweaked out yet.
Sorry looked again and the 36% was reached with two added together for ipilimumab.
So unless I am wrong if Genta backs up results on this trial it will beat ipilimumab in response for stage 4 in the indicated patients.
Seems to be a solid performer.
I remember the MD Anderson people talking about harnessing the immune system. Works different, another tool in the box. If I remember correctly currently treatments like this need extensive monitoring due to the treatment can have very toxic reactions. Don't take that as cardinal rule, I will have to reread.
Here is some more on that. Another tool in the box.
The immune system is a powerful natural agent against cancer. Cytotoxic T lymphocyte antigen 4 (CTLA-4), a key negative regulator of T-cell responses, can restrict the antitumor immune response. Ipilimumab (MDX-010) is a fully human, monoclonal antibody that overcomes CTLA-4–mediated T-cell suppression to enhance the immune response against tumors. Preclinical and early clinical studies of patients with advanced melanoma show that ipilimumab promotes antitumor activity as monotherapy and in combination with treatments such as chemotherapy, vaccines, or cytokines. Emerging data on the kinetics of response to ipilimumab and associated adverse events are increasing our understanding about how to manage patients treated with this therapy. For example, short-term tumor progression prior to delayed regression has been observed in ipilimumab-treated patients, and objective responses may be of prolonged duration. In some patients clinical improvement manifests as stable disease, which may also extend for months or years. Immune-related adverse events (IRAEs) have been observed in patients after CTLA-4 blockade and most likely reflect the drug mechanism of action and corresponding effects on the immune system. Early clinical data suggest a correlation between IRAEs and response to ipilimumab treatment. This paper briefly reviews the results from several ongoing and completed ipilimumab clinical trials, provides a synopsis of current trials, and presents several cases that demonstrate the kinetics of antitumor responses and the relationship to IRAEs in patients receiving ipilimumab.
Everyone is starting to realize this drug has the best chance of any in trials right now for Melanoma. JMHO
I do not know the exact numbers on response, but it was very high.
Knock on wood for us and the patients. I already have my bling order in. LOL
GLA looks to be a good market today.
I hear ya. If the results are looking positive, I think this thing rockets up before the May 27th meeting.
Perfect storm for Genta. Maybe they could get a decision to end the trial early like you stated could happen yesterday. That would be nice. Not counting on it.
This does put more pressure to bear if Genta's trial gets close or same results.
sec filing out